Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea ...

Analysts, including those from Needham and Oppenheimer, flagged risks that Medicare coverage and increasing adoption of GLP-1 therapies could reduce demand for ResMed’s core CPAP devices over time.